中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2014年
12期
1083-1085
,共3页
强直性脊柱炎%注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白%柳氮磺吡啶
彊直性脊柱炎%註射用重組人Ⅱ型腫瘤壞死因子受體-抗體融閤蛋白%柳氮磺吡啶
강직성척주염%주사용중조인Ⅱ형종류배사인자수체-항체융합단백%류담광필정
Ankylosingspondylitis%Recombinant human interferon typeⅡtumor necrosis factor receptors%Sulfasalazine
目的:探讨注射用重组人Ⅱ型肿瘤坏死因子受体?抗体融合蛋白联合柳氮磺吡啶治疗强直性脊柱炎的临床效果。方法:选取2012年1月—2014年1月期间来大连市第二人民医院(以下简称“我院”)就诊的强直性脊柱炎患者100例,按照随机数字表法分为对照组和观察组各50例。对照组患者使用柳氮磺吡啶治疗;观察组患者使用注射用重组人Ⅱ型肿瘤坏死因子受体?抗体融合蛋白联合柳氮磺吡啶治疗,3个月为1个疗程。结果:经过1个疗程的治疗,2组患者强直性脊柱炎病情活动指数( BASDAI )评分、关节肿胀程度、晨僵时间、红细胞沉降率( ESR)、C反应蛋白水平( CRP)均有所下降。观察组患者临床缓解情况优于对照组,2组差异有统计学意义(P<0?05);观察组总有效率为94%(47/50),高于对照组的70%(35/50),2组差异有统计学意义(P<0?05)。结论:注射用重组人Ⅱ型肿瘤坏死因子受体?抗体融合蛋白联合柳氮磺吡啶治疗强直性脊柱炎,临床效果良好,值得临床推广。
目的:探討註射用重組人Ⅱ型腫瘤壞死因子受體?抗體融閤蛋白聯閤柳氮磺吡啶治療彊直性脊柱炎的臨床效果。方法:選取2012年1月—2014年1月期間來大連市第二人民醫院(以下簡稱“我院”)就診的彊直性脊柱炎患者100例,按照隨機數字錶法分為對照組和觀察組各50例。對照組患者使用柳氮磺吡啶治療;觀察組患者使用註射用重組人Ⅱ型腫瘤壞死因子受體?抗體融閤蛋白聯閤柳氮磺吡啶治療,3箇月為1箇療程。結果:經過1箇療程的治療,2組患者彊直性脊柱炎病情活動指數( BASDAI )評分、關節腫脹程度、晨僵時間、紅細胞沉降率( ESR)、C反應蛋白水平( CRP)均有所下降。觀察組患者臨床緩解情況優于對照組,2組差異有統計學意義(P<0?05);觀察組總有效率為94%(47/50),高于對照組的70%(35/50),2組差異有統計學意義(P<0?05)。結論:註射用重組人Ⅱ型腫瘤壞死因子受體?抗體融閤蛋白聯閤柳氮磺吡啶治療彊直性脊柱炎,臨床效果良好,值得臨床推廣。
목적:탐토주사용중조인Ⅱ형종류배사인자수체?항체융합단백연합류담광필정치료강직성척주염적림상효과。방법:선취2012년1월—2014년1월기간래대련시제이인민의원(이하간칭“아원”)취진적강직성척주염환자100례,안조수궤수자표법분위대조조화관찰조각50례。대조조환자사용류담광필정치료;관찰조환자사용주사용중조인Ⅱ형종류배사인자수체?항체융합단백연합류담광필정치료,3개월위1개료정。결과:경과1개료정적치료,2조환자강직성척주염병정활동지수( BASDAI )평분、관절종창정도、신강시간、홍세포침강솔( ESR)、C반응단백수평( CRP)균유소하강。관찰조환자림상완해정황우우대조조,2조차이유통계학의의(P<0?05);관찰조총유효솔위94%(47/50),고우대조조적70%(35/50),2조차이유통계학의의(P<0?05)。결론:주사용중조인Ⅱ형종류배사인자수체?항체융합단백연합류담광필정치료강직성척주염,림상효과량호,치득림상추엄。
OBJECTIVE:To explore the clinical efficacy of recombinant human interferon type Ⅱ tumor necrosis factor receptors plus sulfasalazine for ankylosing spondylitis. METHODS:100 patients with ankylosing spondylitis in our hospital from January 2012 to January 2014 were randomly divided into control group and experimental group, with control group given sulfasalazine alone and the experimental group given etanercept plus sulfasalazine for 3 months( a course of treatment ) . RESULTS: After treatment of one course, both groups showed reduction in BASDAI score, degree of joint swelling, duration of morning stiffness, erythrocyte sedimentation rate and C?reactive protein;however, the patients in the experimental group showed better clinical remission than in the control group and the difference between the two groups was significant(P<0?05); the total effective rate in the experimental group was significantly higher than in the control group [ 94%( 47/50 ) vs. 70%( 35/50 ) ] and the difference between the two groups was significant ( P <0?05 ) . CONCLUSIONS: Etanercept plus sulfasalazine showed remarkable efficacy for ankylosing spondylitis, which thus is worthy of popularization in clinical application.